Pharmaceuticals News and Research

RSS

HA fillers will see highest growth among facial injectable products in 2013 rebound

According to Millennium Research Group, the global authority on medical technology market intelligence, poor economic conditions will limit growth of the European facial injectables market in 2011 and 2012 down to 2.5 percent per year, but the market will rebound strongly in 2013 and onward, reaching a rate of nearly 12 percent by 2016, for a total market of $420 million.

19 Dec 2011

Newgen acquires novel oncology development programs from Kanion

NewGen Therapeutics, Inc. today announced the acquisition of three novel oncology development programs from Kanion USA, Inc. and Kanion Pharmaceutical Co., Ltd..

19 Dec 2011

GSK initiates rhACE2 phase IIa study for Acute Lung Injury

APEIRON Biologics AG announced today that GlaxoSmithKline, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has initiated a phase IIa study in patients suffering from Acute Lung Injury.

19 Dec 2011

Zalicus commences Z944 Phase 1 clinical trial for treatment of acute and inflammatory pain

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of Z944, a novel oral T-type calcium channel blocker with demonstrated preclinical potential for the treatment of acute and inflammatory pain.

19 Dec 2011

Patheon fourth quarter revenues increase to $181.6 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.

19 Dec 2011

Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial

Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

19 Dec 2011

arGEN-X to advance SIMPLE Antibody platform for treatment of autoimmune disorders

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today it has received a grant of €1.3 million to further advance its powerful discovery platform for addressing challenging disease targets.

19 Dec 2011

Research reveals role of government funding in pharmaceutical R&D

Research conducted by Columbia Business School Professor Frank Lichtenberg, Courtney C. Brown Professor of Business, Finance and Economics, Healthcare and Pharmaceutical Management Program, and Bhaven Sampat, Assistant Professor in the Department of Health Policy and Management at the Mailman School of Public Health of Columbia University, identifies the respective contributions of direct and indirect government support in research and development of new pharmaceutical drugs.

16 Dec 2011

Microvascular stamp stimulates, directs blood vessel growth on wound surface

Researchers have developed a bandage that stimulates and directs blood vessel growth on the surface of a wound. The bandage, called a "microvascular stamp," contains living cells that deliver growth factors to damaged tissues in a defined pattern. After a week, the pattern of the stamp "is written in blood vessels," the researchers report.

16 Dec 2011

Drugmakers get more time to record gifts to doctors

U.S. drugmakers and device companies got an extension on the deadline to record all payments and gifts to doctors because of a delay in a proposed rule from health officials.

16 Dec 2011

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

Readmission rates and hospitalization use linked

A new study finds that efforts to keep patients from being readmitted to the hospital might involve efforts to keep them out in the first place.

16 Dec 2011

FDA accepts Vertex KALYDECO NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KALYDECOTM (ivacaftor) and granted the company's request for six-month Priority Review.

16 Dec 2011

Positive results from Hatchtech's DeOvo Phase 2b trial on head lice

Specialty pharmaceutical company Hatchtech Pty Ltd today announced positive results for its Phase 2b clinical trial in subjects with head lice infestation. The results confirmed that DeOvo, a topical head lice treatment, is both safe and highly effective following a single application.

15 Dec 2011

New drug candidate may halt mental decline of Alzheimer's

A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings of a study published today in PLoS one.

15 Dec 2011

MPC project to study how plant genes contribute to producing medicinal compounds

Scientists are about to make publicly available all the data they have so far on the genetic blueprint of medicinal plants and what beneficial properties are encoded by the genes identified.

15 Dec 2011

AtheroNova establishes clear development plan for AHRO-001 after positive FDA feedback

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.

15 Dec 2011

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

ViroPharma Incorporated today announced the modernization of labeling for Vancocin (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application.

15 Dec 2011

Isis announces addition of three new drug development candidates

Isis Pharmaceuticals, Inc. announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.

15 Dec 2011

Antioxidant can delay onset of all indicators of Alzheimer's

When you cut an apple and leave it out, it turns brown. Squeeze the apple with lemon juice, an antioxidant, and the process slows down. Simply put, that same "browning" process-known as oxidative stress-happens in the brain as Alzheimer's disease sets in. The underlying cause is believed to be improper processing of a protein associated with the creation of free radicals that cause oxidative stress.

15 Dec 2011